Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines current literature on botulinum toxin type A for androgenetic alopecia, reporting an association with increased hair growth and improved hair density, though further research is needed.

This study suggests that using the International Psoriasis Council's classification, which includes body surface area, special areas, and treatment history, may identify more candidates for systemic therapy than by body surface area alone.

This review highlights the various nonmedical uses of anabolic androgenic steroids and associated polypharmacy, suggesting that preventing their abuse should be a public health priority, but it reports no new findings.

Botulinum toxin is not effective for treating male hair loss.

This abstract provides information about the American Board of Hair Restoration Surgery as the only internationally accepted certifying body for hair restoration surgeons, but it reports no new research results.

This study found that the STRIAA scoring tool provides a rapid and highly reliable assessment of alopecia areata severity, showing a significant correlation with the traditional SALT score, thus enhancing clinical evaluation in patients with this condition.

This study introduces a novel computational model using fuzzy logic and multi-criteria decision-making techniques to create a triage system for androgenetic alopecia management, stratifying patients into seven severity levels and aiding in resource allocation and treatment planning.

This article discusses the patterns and variants of alopecia areata, including the rare sisaipho, but reports no new research findings.

This case report describes a patient with severe alopecia totalis and atopic dermatitis who showed almost complete hair regrowth and improved skin lesions after receiving subcutaneous allergen-specific immunotherapy using house dust mites.

This article highlights the growing demand for trained surgical assistants in the rapidly expanding field of hair restoration, reporting no new clinical results.

In this study, 4‐MAPC treatment reduced ventral prostate weight in rats primarily through decreased synthetic activity, with testosterone propionate increasing prostate weight and activity at pharmacologic doses.

This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.

This study observed that oral tofacitinib was effective and safe for treating alopecia areata in paediatric patients, with 82% of pre-adolescent participants experiencing hair regrowth and 64% showing significant improvement in their hair loss severity scores.

In in-vitro experiments, this study found that poncirin showed higher inhibitory activity against JAK3 than tofacitinib, suggesting potential for alopecia areata treatment.

This case series observed that five Black pediatric patients with moderate to severe alopecia areata showed significant hair regrowth and minimal disease activity after treatment with topical JAK inhibitors, vitamin D supplementation, and antihistamines, with additional therapies in some cases.

This article reviews the challenges in treating hidradenitis suppurativa and discusses potential treatment options, emphasizing the need for increased awareness and comprehensive care, but reports no new clinical results.

This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.

This study found that their newly developed ADRL framework significantly improved the accuracy of scalp tissue layer segmentation in HR-MR images compared to existing methods.

In this updated guideline, the British Association of Dermatologists' expert group provided 49 management recommendations for alopecia areata and highlighted future research priorities, aiming to improve care for individuals affected by this condition.

This article reviews treatments for progeria, including aspirin, hydrotherapy, and farnesyl transferase inhibitors, but reports no new clinical results.

This abstract contains only author affiliations and mentions the Asian Association of Hair Restoration Surgeons, without presenting any new research findings.

This research found that certain inflammasome proteins, like caspase-1, ASC, IL-18, and IL-1β, were elevated in patients with aneurysmal subarachnoid hemorrhage (aSAH) compared to controls and suggested these proteins could serve as reliable biomarkers for inflammation, potentially predicting worse outcomes.

This case report describes a 29-year-old woman with Female Pattern Hair Loss whose hair thinning reduced one month after botulinum toxin treatment.

This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.

This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.

This review discusses various treatments for androgenic alopecia, highlighting FDA-approved options and other commonly used therapies, but reports no new clinical results.

This case study reports a 15-year-old female diagnosed with traumatic anserine folliculosis linked to prolonged friction on the chin, with improvement noted upon adjusting behaviors causing pressure.

This case report suggests that intradermal botulinum toxin type A may alleviate pruritus and reduce papules in Fox-Fordyce disease, improving quality of life without serious adverse effects for at least six months.

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.